These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16127057)

  • 1. Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.
    Fujimoto-Nakamura M; Ito H; Oyamada Y; Nishino T; Yamagishi J
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3810-5. PubMed ID: 16127057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.
    Vickers AA; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2007 Aug; 60(2):269-73. PubMed ID: 17556355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
    Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
    J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
    Beeton ML; Chalker VJ; Kotecha S; Spiller OB
    J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
    Couzinet S; Yugueros J; Barras C; Visomblin N; Francois P; Lacroix B; Vernet G; Lew D; Troesch A; Schrenzel J; Jay C
    J Microbiol Methods; 2005 Feb; 60(2):275-9. PubMed ID: 15590102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.
    Dupont P; Aubry A; Cambau E; Gutmann L
    J Bacteriol; 2005 Feb; 187(4):1536-40. PubMed ID: 15687222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
    Grohs P; Podglajen I; Gutmann L
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3024-7. PubMed ID: 15273116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin.
    Sanfilippo CM; Hesje CK; Haas W; Morris TW
    Chemotherapy; 2011; 57(5):363-71. PubMed ID: 21996946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.
    Stieger M; Angehrn P; Wohlgensinger B; Gmünder H
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1060-2. PubMed ID: 8849232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.
    Hardy CD; Cozzarelli NR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):941-7. PubMed ID: 12604525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica.
    Eaves DJ; Randall L; Gray DT; Buckley A; Woodward MJ; White AP; Piddock LJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4012-5. PubMed ID: 15388468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic novobiocin resistance in Staphylococcus saprophyticus.
    Vickers AA; Chopra I; O'Neill AJ
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4484-5. PubMed ID: 17876001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.